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ABSTRACT  
   
Multiple Sclerosis, an autoimmune disease, is one of the most common 
neurological disorder in which demyelinating of the axon occurs. The main 
symptoms of MS disease are fatigue, vision problems, stability issue, balance 
problems. Unfortunately, currently available treatments for this disease do not 
always guarantee the improvement of the condition of the MS patient and there 
has not been an accurate mechanism to measure the effectiveness of the 
treatment due to inter-patient heterogeneity. The factors that count for varying 
the performance of MS patients include environmental setting, weather, 
psychological status, dressing style and more. Also, patients may react differently 
while examined at specially arranged setting and this may not be the same while 
he/she is at home. Hence, it becomes a major problem for MS patients that how 
effectively a treatment slows down the progress of the disease and gives a relief 
for the patient. This thesis is trying to build a reliable system to estimate how 
good a treatment is for MS patients. Here I study the kinematic variables such as 
velocity of walking, stride length, variability and so on to find and compare the 
variations of the patient after a treatment given by the doctor, and trace these 
parameters for some patients after the treatment effect subdued. 
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Chapter 1 
INTRODUCTION 
Multiple sclerosis (MS), also known as "disseminated sclerosis", is an 
inflammatory disease in which the fatty myelin sheaths around the axons of the 
brain and spinal cord are damaged, leading to demyelination and scarring as well 
as a broad spectrum of signs and symptoms.[1] 
Almost any neurological symptom can appear with the disease, and often 
progresses to physical and cognitive disability.[2] MS takes several forms, with 
new symptoms occurring either in discrete attacks (relapsing forms) or slowly 
accumulating over time (progressive forms). 
Symptoms of MS usually appear in episodic acute periods of worsening (called 
relapses, exacerbations, or attacks), in a gradually progressive deterioration of 
neurologic function, or in a combination of both.[3] Viral infections such as the 
common cold, influenza, or gastroenteritis increase the risk of relapse.[1] Stress 
may also trigger an attack.  
Cure for multiple sclerosis has not been discovered yet. Normally, treatments are 
dedicated to return function after an attack, prevent new attacks, and prevent 
disability. In the laboratory, objective and quantitative methods are adopted in 
evaluating the gait pattern changes and this is efficient and cost effective too. 
Motion analysis is a type of technique used to capture the patient's motion using 
the various camera kept at different angles. But this is an expensive set-up to be 
bought by the clinic or for home purposes. The other major barrier in effectively 
monitoring the progression or relief of the disease using the quantitative methods 
is that the MS disease is highly variable involving various factors such as 
environmental setting, weather, psychological status, fatigue. For instance, there 
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was an overall decline in the performance of patients with MS (PwMS) who have 
additive cognitive tasks by processing their gait data (Sosnoff JJ, Boes MK, 
2011). The patient may react differently while examined at specially arranged 
setting and this may not be the same while he/she is at home. Even different 
style of dressing can affect the performance of MS patients: it has been proved 
that textured insoles can produce improvements in stride length (Dixon J, 
Gamesby H, 2011).  
Numerous previous researches have been done about the conditions and 
treatments of MS patients. Normally, patients are required to take some clinical 
tests or do a serial of exercise before recording their data, like the Coefficient of 
Variation (CoV) and the Approximate Entropy (ApEn) (Kaipust JP, 2012). Here I 
study the kinematic variables such as velocity of walking, stride length and 
stability to find the variations of the patient after a treatment given by the doctor. I 
am taking all the factors mentioned above into consideration and building a cost 
effective wireless sensor system such the parameters I get from the sensor is 
easily monitored through a mobile.  What’s new in this research is that I plan to 
use fewer sensors to monitor the selected important parameters instead of 
requesting patients to carry these sensors all over body (e.g. waists, ankles, 
elbows, etc) (Spain RI, St George RJ, 2012). These can be transmitted through 
the doctor such that the doctor can monitor the day to day activities of the 
patient, while the patient is at home. 
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                                                         Chapter 2 
LITERATURE REVIEW 
Multiple Sclerosis  
Since this research is to analysis the quantifiable gait parameters of multiple 
sclerosis patients, it is extremely important to understand what is multiple 
sclerosis, what kind of symptoms will MS patients have, what factors will 
influence the performance of MS patients and so forth.  
Whereas I have talked about the possible symptoms that MS patients may have, 
I will start with the treatment or drugs that may improve the physical functions of 
MS patients. When it comes to the treatment for PwMS, Joseph R. Berger (2011) 
has published a comprehensive and prominent review about some weighted 
drugs to relieve the symptoms of this disease. He mainly classified all these 
drugs into 3 categories: Disease-modifying treatments (DMTs), Corticosteroids, 
and Dalfampridine. Moreover, this paper also illustrates whether these drugs 
could contribute to improve the quality of life (QOL). 
The first category, disease-modifying treatments, mainly contains five drugs that 
are normally applied in clinic.  
Interferon-beta (IFNB) is a cytokine primarily secreted by fibroblasts as part of 
immune response, and it can be reproduced by recombinant DNA technology in 
therapies. In MS, the IFNB is thought to act by involving modulating immune 
system through interactions with specific cell-surface receptors. The shortage of 
this drug includes that its effect could be lessen in some patients who develop 
neutralizing antibodies over time. 
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Glatiramer acetate (GA) is a synthetic analog of myelin basic protein, the MS-
associated antigen. GA mechanism seems to induce a shift in cytokine 
production toward secretion of anti-inflammatory cytokines. 
Natalizumab is a monoclonal antibody that blocks lymphocyte entry into the 
central nervous system. What seems more appealing is that adding natalizumab 
to IFNB-1a further reduced relapse rate and disability progression compared with 
treating with IFNB-1a alone, which provides an insight about how to improve the 
efficiency of treatment. Unfortunately, this drug may cause progressive multifocal 
leukoencephalopathy (PML), which leads to the manufacturer suspended 
marketing. 
Mitoxantrone, an immunosuppressant, reduces lymphocyte proliferation via 
several mechanisms. Similar to Natalizumab, some serious side effects like 
decreased systolic function, heart failure prevent the wide use of this drug. 
Fingolimod, an immunomodulator originally used in organ transplantation, is 
marketing as an oral drug. Evidence show that an oral DMT have apparent QOL 
advantages over injected therapies, especially for newly diagnosed patients who 
could benefit from early intervention to delay progression. Again, the safety 
concerns block fingolimod from being the oral therapy that presumably replaces 
injected agents since the patients may experience fatal infection, atrioventricular 
block, and elevation of liver enzymes. 
Whereas DMTs reduce the rate and severity of relapses, the accumulation of 
brain and spinal cord lesions detected by magnetic resonance imaging (MRI), 
and disability progression as measured by Expanded Disability Status Scale 
(EDSS), relatively few DMT trials documented QOL improvement with QOL 
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metrics. Hence, even some patients report poor quality of life (QOL), and 
adverse effects (AEs), clinicians still appreciate the effects of DMTs.  
The second category he introduced is corticosteroids. Corticosteroids have anti-
inflammatory effects that reduce severity and duration of acute relapses, but do 
not affect the disease course. They have been shown to speed relapse recovery 
in several trials. Corticosteroid treatment commonly begins with intravenous 
methylprednisolone, followed by tapering oral prednisone; high-dose oral steroids 
have also been used. QOL scores on MSQOL-54 and MS Functional Composite 
have improved with methylprednisolone treatment of relapses. 
The last drug that proved to be effect in MS treatments is Dalfampridine, which 
takes effect by blocking the voltage-dependent potassium channels on the 
surface of demyelinated nerve fibers. Its marketing name, Ampyra, received FDA 
approval for all forms of MS specifically to improve walking, which was 
demonstrated by increased walking speed. Dalfampridine does not address 
disease modification, but can be used with DMTs and other medications. The 
active ingredient in dalfampridine is 4-aminopyridine (4-AP), which proved to be 
potent for elevating patient’s QOL and satisfaction even before the development 
of dalfampridine for MS.  
Before that, Filippini G. Brusaferri F (2009) had published a review about the 
efficacy and safety of corticosteroids or adrenocorticotrophic hormone (ACTH) in 
reducing the short and long term morbidity from MS. In this research, they 
selected lists of articles, undertook handsearching, and contacted trialists and 
pharmaceutical companies without any age or severity restrictions for the 
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patients. The drugs analysed were methylprednisolone (MP) (four trials, 140 
participants) and ACTH (two trials, 237 participants). 
Overall, the results show that MP or ACTH indeed has a protective effect against 
the MS disease getting worse within the first five weeks of treatment with some 
but non-significant greater effect for MP and intravenous administration. Besides, 
the duration of treatment (5 days vs. 15 days) with MP did not show any 
significant difference. However, data are insufficient to accurately estimate effect 
of corticosteroids on prevention of new exacerbations. In terms of long-term 
progression, no data are available beyond one year of follow-up to indicate 
whether steroids or ACTH have any lasting benefit or aside effect. 
 
Gait of MS patients 
As gait is an extremely important parameter in measuring and monitoring the 
walking pattern of MS patients, R.I. Spaina, and R.J. St. Georgeb (2011) 
conducted an experiment to investigate the gait of subjects with any type of MS 
and normal T25FW (Timed 25 Foot Walk, used in the MS clinic) by body-worn 
sensors.  
In this research, thirty-one subjects need to complete four tasks: Timed 25 Foot 
Walk (walk 25 feet in a hallway); Timed-Up-and-Go test (stand up from a chair, 
walk 7 m, turn, then walk back and sit down); Quiet standing task (stand with 
arms crossed and feet placed by a template block for 30 seconds, three trials 
with eyes open and three with eyes closed); Self-reported balance and walking 
measures ( subjects complete 3 reports: one is designed to predict falls in the 
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MS population, one is to reflect the impact of MS on walking , and the last is to 
rate the neurological function in MS patients). 
The results show that during gait, people with MS had increased trunk roll of 
motion, which means PwMS are harder to control their dynamic balance and 
easier to cause instability. Meanwhile, PwMS spend significant longer time during 
turnings suggesting an impaired proprioceptive system. The reason is extra 
weighting may be placed on the proprioceptive systems when a head turns in 
preparation for body turn. On the other hand, sway acceleration amplitude 
increased more in people with MS with eyes closed condition during quiet stance, 
and they concludes that PwMS have a greater reliance on visual input due to 
loss of other balance maintenance functions.  
In order to comprehend the gait features of PwMS who don’t have normal 
walking speed, Jacob J. Sosnoff and Brian M. Sandroff (2012) compared the gait 
of PwMS who have mild disability and healthy subjects. 
86 participants were selected in this research, half of the sample had mild 
multiple sclerosis (MS group, had a median EDSS score of 2.0 of a 0-10 scale) 
and the remaining half were healthy subjects. These participants were told to 
complete four walking trials along a 26-foot GAITRite™ (a commercially available 
gait analysis system) mat at a self-selected pace. The parameters recorded 
includes functional ambulation profile (FAP), cadence (steps/min), velocity (cm/s), 
step length (CM), step time (s), base of support (cm), and intra-individual 
variability based on coefficient of variability (CV) of those parameters. The results 
show that MS patients have a significant lower velocity, shorter step length, 
larger base of support than controls. Besides, the CV of step length and step 
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time is much larger in MS patients than in controls, which means MS patients 
have a relatively unstable velocity and stride length.  
Hence, they concluded that patients with even mild MS (not defined as clinical 
gait impairment by EDSS evaluation) still have detectable differences in gait with 
utilizing GAITRite technology. Besides, from the CV of these parameters, they 
assume that these patients with MS (PwMS) had greater step time variability and 
single support time variability than controls might reflects mobility impairment 
and/or falls in PwMS.  
Moreover, some inconspicuous factors may affect the gait of PwMS. Dixon J and 
Hatton AL (2011) have found that textured insole is one of these factors that can 
produce improvement on gait in PwMS.  Their previous studies have shown that 
footwear, including textured insoles, may improve postural stability in healthy 
young and older adults (Palluel et al., 2008; Hatton et al., 2009; Hatton et al., 
2011). 
Forty-six people with MS (34 women) were randomized to one of two textured 
insole groups: texture A, which was used in their previous studies, or texture B, a 
commercial insole. These participants were then required to walk along the same 
gait analysis system as Jacob J. Sosnoff and Brian M. Sandroff  (2012) used 
(GaitRiteTM). Afterwards, they need to wear the insoles for two weeks and 
returned for repeat testing. 
The results show that stride length increased between baseline and follow-up in 
both legs in group A and group B. However, both velocity and cadence did not 
change significantly in either group. They think this implies that textured insoles 
can at least improve MS patients’ stride length.
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Chapter 3 
METHOD  
3.1 Trials of each patient 
Here I focus on analyzing the various gait parameters of five MS patients who 
have been given the treatment of corticosteroids. I collected the data of two 
patients under before and after treatment conditions, while the other three 
patients’ data is collected under before, after and follow up treatment conditions.  
Meanwhile, some patients are tested with shoes on only, and others are tested 
with both shoes on and shoes off. The table below concludes the condition under 
which the patients are tested. 
Table 1: The number of patients under each condition 
 Before and after treatment 
only 
Before, after and follow up 
treatment 
Shoes on only 1 1 
Shoes on and 
Shoes off 
1 2 
 
The specific aim for this research is to see how the patient is able to walk before 
the treatment and how is he/she able to respond to the particular treatment given 
by the doctor, which requires analyzing and comparing the data of patients 
before treatments and after treatment.  
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3.2 Inclusion criteria 
Participants included four male and one female MS patients whose age ranged 
from 21 to 65. These patients have either primary or secondary progressive MS, 
with gait disorder as primary manifestation. Their Expanded Disability Status 
Scale (EDSS) score ranged from 4.5 (able to ambulate independently for up to 
300 m) to 6.0 (ability to ambulate up to 100 m with unilateral assistance), with 
change in EDSS of 1 point in the last 12 month based on recorded examinations 
and report. The planned treatment for them is intravenous methylprednisolone 
(1000 mg/d x five days). [11] 
Evaluations: 
Clinical: neurological examination, EDSS, ambulation index, timed 25-foot gait, 
PASAT [Paced Auditory Serial Addition Test; a standard MS clinical outcome], 
gait phenotype classification (spastic, ataxic, or spastic-ataxic), and assessment 
of quality of life (SF-36 questionnaire) and fatigue (MSFS; MS-Specific Fatigue 
Scale). Participants will rate their post-treatment response on a 7 point rating 
scale from -3 (much worse gait) to +3 (much better), where zero represents no 
effect. This assessment will be performed three (3) times at Mayo Clinic: up to 14 
days pre-treatment; 3-7 days post-treatment onset; and up to 6 months post-
treatment. [11] 
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3.3 Experimental setup 
The twenty markers attached on the patients allowed the reconstruction of 
individual joint angles and trajectories of hands and feet in the three dimensional 
space.  
 
Figure 1: Placement of 20 markers 
 
 
Here I used the motion capture system provided by the iStage at Mathews center 
in Arizona State University. Totally ten infrared cameras were used throughout 
the analysis covering the patient's walk path, which includes three long straight 
paths, one short path, one smooth turning and three sharp turnings as shown in 
the figure 2. Each subject is told to walk along the path for 3-5 trials either with 
shoe on only or both shoes on and shoes off. 
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Figure 2: The path that patients work through 
 
The software that was used for this project is Cortex and Evart Motion capture 
system. Mostly Evart was used. Initial calibration of the motion capture system is 
done including L-frame, wand calibration and neutral T-Pose with patient wearing 
all the markers. 
There would be analysis in three phases, 
 Before the treatment- Before giving corticosteroids treatment and figuring 
out how the patient is initially walking. 
 After the treatment - After the treatment and analyzing how the patient 
has responded to the treatment since corticosteroids are used in curing 
the progression of MS disease at least temporarily. 
 Follow up treatment - Another analysis is done after the effect of the 
steroid is completely over in the patient's body to study effectively how the 
treatment has worked and also to verify the results. 
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If some markers were misplaced by the motion capture system, then rectification 
has been done using the software system to correct the marker position. The 
data I obtained were rectified as accurately as possible, but there are still some 
markers are missing, especially in the 4th straight path in some trials. 
 
3.4 Body coordinate system 
Body coordinate system is used to determine the position of each part of the 
body with the center, or the origin, is fixed on body. This system is also 
constructed by 3 dimensional axes: determine x(facing), y(vertical), z(lateral) axis.  
As long as I have defined 2 axes, the third one can be calculated as the 
orthogonal vector to the plane formed by those 2 axes. Hence, here I am trying to 
define and calculate facing direction, which is x axis, and lateral direction, which 
is z axis. 
A. Find Facing Direction 
The facing direction is the orthogonal vector to the plane formed by three 
markers on the lower back. It is computed as the cross product of RPvec and 
LPvec (see Figure 1), and defined as FDvec.  
FDvec = RPvec x LPvec 
B. Find Lateral Direction 
The lateral direction of body is determined by RPvec, LPvec as well as back2 
marker. Since the left pelvis marker and the right pelvis marker are presumably 
not placed symmetrically, I figured out a way to find the point that is symmetric to 
left pelvis. 
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Figure 3: Reconstruct body coordinates 
 
v1=R-pelvis – L-pelvis 
v2=later axis (z axis)  
v3=R-pelvis – back2 
v4=L-pelvis – back2 
Basically, I built 3 equations to determine v2 (a, b, c), which has 3 variables. 
(1) The length of v2 is fixed 
 
2 2 2 1/2( 2) ( )norm v a b c       
Where norm( 2) 2* ( 4)*sin( / 2)v norm v alpha , and 
arccos( 3 4 / ( 3)* ( 4))alpha v v norm v norm v       
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(2) The angle between v1 and v2 is theta, which is about 6 degrees (calculated 
from T-pose)          
 a* 1. * 1. * 1. ( 2)* ( 1)*cos( )v x b v y c v z norm v norm v theta    
(3) The angle between v2 and v3 is gamma (which is beta plus theta). 
a* 4. * 4. * 4. ( 4)* ( 1)*cos(180 )v x b v y c v z norm v norm v gamma     
Where  
gamma beta theta   
180 arccos( 1 4 / ( 1)* ( 4))beta v v norm v norm v    
Or  
gamma (180 ) / 2alpha   
 
 
 
3.5 Velocity calculation 
For each individual straight path, start and end frames are noted from the stick 
diagram. A new coordinate system is defined with respect to the start frame. 
Thus the start frame becomes the origin with respect to the other frames for both 
the x and z axis in the global coordinate system. The position vector (dz and dx) 
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in the z and x axis respectively is calculated by two point differentiation methods 
and to give the velocity vector at that instant.  
velvector=(b(x+t)-b(x))/ t.  
where, b denotes the back2 marker position vector and t is the time difference 
between them (x+t and x). The velocity magnitude is thus calculated from them. 
Inasmuch as back2 marker stands around the central point of human body and 
presents in almost all the frames throughout the walking trials, it would be more 
accurate to calculate the velocity by using it.  
 
 
 
3.6 Gait segment and stride length 
With the assumption that patients touch the ground with their heels first, I use the 
time point as soon as the y-axis value of left/right heel reaches the lowest to 
segment gait cycles, which means these time points are the ending frames of 
current gaits as well as the starting frames of next gaits. Since the patterns of 
gaits are different from patients to patients and also vary between shoes on and 
shoes off conditions, I manually adjust the parameters to select the right 
positions of time points. 
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Figure 4: Adjustments for time points  
 
 
  
         Before adjustment                    
 
 
 
 
 
 
                                           After adjustment 
 
 
 
 
 
After recording the right time points, I calculate the distance between the markers 
on heels at two consecutive time points in global coordinate system as the stride 
length. On the other hand, I recorded the starting and the ending frame number 
of each straight path and each turning so that I can analysis the data separately.   
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Chapter 4 
DATA ANALYSIS AND RESULTS 
4.1 Velocity 
      
                                   Table 2: Mean of the patient’s velocity      
 
                                     Table 3: CV of the patient’s velocity 
 
Generally, I compare the mean of each patient’s velocity as well as the 
coefficient of variation of each patient’s velocity. The results show that 4 out of 5 
patients have a higher average velocity after treatment compared to before 
treatment for both shoes on and shoes off conditions. However, the change of 
coefficient of variation depends on individuals and whether the patients are 
wearing shoes. With shoes on, the data of 3 out of 5 patients (*) indicates their 
velocity is more stable after treatment (with a decreased CV of velocity). Star 
Subject Before Treatment Post Treatment Follow up 
 Shoes Off Shoes on Shoes off Shoes on Shoes off Shoes on 
A 0.619 0.631 0.545 0.589 0.655 0.696 
B 0.639 0.716 0.75 0.773 0.73 0.773 
C NA 0.989 1.16 1.12 NA NA 
D 0.686 0.649 0.717 0.696 NA NA 
E NA 0.787 NA 0.836 NA 0.797 
Subject Before Treatment Post Treatment Follow up 
 Shoes Off Shoes on Shoes off Shoes on Shoes off Shoes on 
A 28.17 30.78 28.55 25.67 20.59 21.87 
B 19.93 14.22 18.08 16.36 21.75 17.68 
C NA 24.62 18.18 22.17 NA NA 
D 26.33 28.26 27.34 34.44 NA NA 
E NA 25.81 NA 23.4 NA 22.32 
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marker in the brackets indicates that patient A is included in this group. 
Meanwhile, only 1 out of 3 patients with shoes off has a significant decrease in 
CV of velocity after treatment. 
In terms of follow up condition, I have 3 out of those 5 patients come back about 
3 months after treatment. Among these 3 patients, 2 patients have lower average 
velocity and that one who reports he felt worse after treatment actually have a 
higher velocity compared to after treatment, which means he “recovers” from the 
treatment. When it comes to CV of velocity, the results are not the same for all 
the patients. For 3 patients under shoes on condition, 2 of them (*) have a more 
stable velocity compared to after treatment. While 1 of 2 patients (*) under shoes 
off condition have a more stable velocity.  
From the analysis above, I can see that patients do have a greater velocity after 
treatment, but it is not sure whether they will have a more stable walking speed 
after treatment. However, this treatment doesn’t have a significant or unified 
effect on the variability of velocity for all the patients.  
Also, shoes have different effects on patients as the terms of the variability of 
velocity. Most of the data suggests shoes will impair the variability of velocity, but 
one of these patients have a more stable velocity with shoes on under all 3 
conditions: before treatment, after treatment, and follow up conditions. 
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4.2 Stride Length 
 
Table 4: Mean of the patient’s stride length 
           Subject Before Treatment Post Treatment Follow up 
 Shoes off Shoes on Shoes off Shoes on Shoes off Shoes on 
A 807.70 847.70 790.20 869.20 822.50 932.65 
B 755.70 863.90 831.10 947.60 859.40 998.80 
C NA 1191.10 1200.30 1186.10 NA NA 
D 844.40 846.50 988.50 968.40 NA NA 
E NA 868.90 NA 934.90 NA 884.30 
 
     
 
                              Table 5: CoefVar of the patient’s stride length 
     
 
Subject Before Treatment Post Treatment Follow up 
 Shoes off Shoes on Shoes off Shoes on Shoes off Shoes on 
A 17.57 16.92 16.12 14.56 16.69 9.51 
B 18.18 19.92 22.43 19.21 21.17 19.56 
C NA 20.89 27 26.92 NA NA 
D 25.1 20.3 13.96 25.16 NA NA 
E NA 22.96 NA 20.44 NA 19.71      
      
      
Similar to the analysis of velocity, I compare the mean of each patient’s stride 
length as well as the coefficient of variation of their stride length. The results also 
show that 3 out of 5 patients have a larger average stride length after treatment 
compared to before treatment for both shoes on and shoes off conditions. The 
only one who has a significant smaller average stride length is patient A, who 
reported this treatment worsen his condition. The change of coefficient of 
variation also depends on individuals and whether the patients are wearing 
shoes. With shoes on, 2 out of 5 patients (*) have a significant improvement as 
the stability of their stride length after treatment (with a decreased CV of stride 
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length), and 1 out of the other three patients have a slightly decline as their mean 
of stride length after treatment. Meanwhile, 2 out of 3 patients (*) with shoes off 
have a significant decrease in CV of stride length after treatment. 
In terms of follow up condition, what attracted me is patient B, who still has a rise 
as his average stride length compared to after treatment condition. I assume this 
presumably caused by some other factors like weather, or the treatment itself.  
When it comes to CV of stride length in follow up condition, the results are not 
the same for all the patients. For 3 patients under shoes on condition, 2 of them 
(*) have a noticeable more stable stride length compared to after treatment, 
whereas the other one has no substantial change.  On the other hand, 1 of 2 
patients under shoes off condition gets better as terms of the stability of stride 
length, while the other one (*) shows no obvious changes.  
From the analysis above, it is disinterested to say that patients predispose to 
have a greater stride length after treatment, while it is not sure whether they will 
have a more stable stride length after treatment. That is to say, this treatment 
doesn’t have a significant or unified effect on the variability of velocity for all the 
patients.  
Also, shoes have different effects on patients as the terms of the variability of 
stride length. Most of the data suggests shoes will impair the stability of velocity, 
but one of these patients have a more stable velocity with shoes on under all 3 
conditions: before treatment, after treatment, and follow up conditions. 
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4.3 Variability 
After converting the global position of all the markers to the body centered 
position, now it is ready to compute range of motion of ten rigid parts of body. 
These ten rigid parts include upperArm, lowerArm, upperLeg, lowerLeg, and foot 
for each side of the body, each rigid body is represented by a vector. The vector 
is calculated from the marker attached on both ends of the rigid body. Then the 
range of motion is the angle between this vector and the plane constructed by 
facing direction and lateral direction of the body.  
The range of motion vector is computed from A-P view (Figure 5) as AP angles: 
In A-P view,        (   ), I define that if   is above horizontal line, it is 
negative, otherwise positive. 
Figure 5: Stick man A-P view 
 
 
 
After calculating ten parameters in total for each patient, I found that upper arms 
and lower arms have the most significant change between before treatment and 
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after treatment, and these four parameters (right upper arm, left upper arm, right 
lower arm, left lower arm) could represent all the parameters in variability 
analysis. This finding can be explained by the free range of motion, which is 
largest for arms when compared with legs and feet.  
 
Table 6: Standard deviation of the patients’ rigid parts performance 
 
 
 
From the table above, it is perspicuous to conclude that the variability issue is 
different from patients to patients. Even so, there are still some rules that could 
be observed from comparing with the CV of patients’ stride length table. If I 
compared the mean of standard deviation of upper arm with the mean of 
standard deviation of lower arm under every single condition, it is easy to obtain 
that this value is always larger in lower arm than in upper arm, this observation is 
consistent with the concept that lower arm has a larger free range and significant 
impact on the balancing system of human. Moreover, the changing between 
before treatment and after treatment is in the same style for upper arm and lower 
arm, which means not only are these two parts correlated to each other, but also 
merely detecting the movement of either one side in the sensor system that will 
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be built in the future is enough.  Whereas the variability pattern of upper arm is 
similar to that of lower arm, the variability pattern of left arm could be completely 
different than that of right arm. For example, the last patient’s left arm moves 
more stable after treatment, while the mean of standard deviation of his right arm 
increases after treatment. However, the treatment has the same effect on the 
variability of first 2 patients’ arms. I assume this is because some patients rely on 
one side of the body to support their weights, and others don’t have a preference 
of which side of the bodies to put their weight on when they are walking. 
As terms of treatment effect, I find that the variability of the patients is somehow 
related to their CV of stride length. For the first patient, his mean of standard 
deviation for both arms go up, which means this treatment has a negative effect 
on his variability, and this result is consistent with his condition he reported. As 
for the second patient, these values also go up as the CV of his stride length 
indicated. The situation is slightly different for the last three patients. Their right 
arm has a larger mean of standard deviation after treatment, whereas their left 
arm acts more stable after treatment.  
 
 
4.4 Power Analysis 
In the following Power Analysis, I consider before treatment data as control 
groups. Specifically, in this research I choose four parameters: mean of stride 
length, CV of stride length, mean of velocity, CV of velocity. These four 
parameters are the most important parameters in this research and in this kind of 
research. Here I listed two primary reasons of why I choose these four 
parameters.  One reason is that CV of stride length and CV of velocity could aptly 
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reflect the variability and stability of the walking, whether the patients' stride and 
velocity went on smoothly. An even more striking reason is that mean of stride 
length and mean of velocity can reflect the "quality" of the walking. Besides, a 
plenty of studies show that patients walk slower and use smaller strides than 
normal people do. 
 
I. Stride Length: before treatment VS after treatment 
Hypothesis 1: Patients have 5% greater stride lengths post treatment 
Hypothesis 2: The variability is 5% smaller post treatment 
 
 Table 7: Power analysis according to patient’s stride length 
 Size Standard 
deviation 
Difference Power Actual 
Power 
Mean of 
stride 
length 
96 135.9 49.06 0.8 0.80158
9 
Variability 
of stride 
length 
177 3.804 1.01 0,8 0.80181
2 
 
 
 
 
 
  
II. Velocity 
Hypothesis 1: Patients have 5% greater velocity post treatment 
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Hypothesis 2: The variability is 5% smaller post treatment 
 
Table 8: Power analysis according to patient’s velocity 
 Size Standard 
deviation 
Difference Power Actual 
Power 
Mean of 
velocity 
235 0.1745 0.04014 0.8 0.800942 
Variability of 
velocity 
338 6.46 1.237 0,8 0.800096 
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                                                          Chapter 5 
DISCUSSION 
 
From all the results above, it is persuasive to point out that the effect of this 
treatment depends on patients. Although there are some parameters, such as 
mean of stride length and mean of velocity, change accordingly for all the 
patients, most variability-related parameters are not consistent with all the 
patients. On the other hand, the variability analysis proves that the arms take 
major responsibility for the balance system of human body. The change of 
variability also depends on the individual patients and their walking habit, which 
is the side(s) they put their weights on while walking.  
As concluded in the velocity and stride length analysis part, the mean of velocity 
increases and the mean of stride length becomes larger for four out of five 
patients (patient B, C, D, E). The reason why patient A has the opposite result of 
these two parameters is probably because that he reported that he felt 
perceptible worse after the treatment. The interesting thing is that his CV of stride 
length and velocity are somehow smaller after treatment, which means he has 
more stable stride after treatment. However, the variability analysis of his data 
shows his performance tends to be more variable after treatment as terms of his 
arms. I guess the explanation underlie this kind of situation is that he walked 
slower and with smaller strides, as well as trying hard to use his arms to keep 
balance, so that he can have a relatively stable stride and walking speed.   
The conditions of the patients are not only related to their physical status, but 
also expressed by their mental status. In this thesis, I only take a mathematical 
computation and statistical analysis to estimate the change of these patients’ 
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physical conditions between before treatment and after treatment, some with an 
extra follow up condition. The future work could relate the physical improvement 
with psychological change, e.g. whether the patients feel better, if they have an 
improvement as quality of life. 
I think there are two major aspects that can be improved for this project. Since I 
only have 5 patients to test in this project, I anticipate reaching more conclusions 
and testifying some precarious ideas when I have more patients, like 150 of them, 
to exam statistically. With more data, I can decide whether the occasion 
described above (patient A) is a rare or common situation, so that I could have a 
deeper insight about the physical condition of the patient who feels worse after 
receiving a treatment, or the negative impact of a treatment as terms of physical 
movement.  
Another aspect that can be improved is the motion capture system. I use 10 
cameras to capture the motion of patients, which causes markers missing in 
some frames, especially for turnings. This could lead to varieties of problems 
such as fail to construct body coordinate system if the back2 marker or left/right 
pelvis marker is missing, or unable to analyses the variability of some rigid parts 
of human body if the corresponding markers are not shown in the stick figure. 
According to my experience and some work form other researchers, 12 cameras 
would be the optimal number. 
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APPENDIX A  
STORAGE OF MAKER SET IN ARRAY 
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 Here is the order of all the 20 markers and their position in array (each take 3 
consecutive bytes for x, y, z). “l” stands for left and “r” stands for right. 
 
Markers Order Minimal Maximum  
back1 1 3 
back2 4 6 
rshoulder 7 9 
relbow 10 12 
rwrist 13 15 
lshoulder 16 18 
lelbow 19 21 
lwrist 22 24 
rwaist 25 27 
lwaist 28 30 
rleg 31 33 
rknee 34 36 
rankle 37 39 
rheel 40 42 
rtoe 43 45 
lleg 46 48 
lknee 49 51 
lankle 52 54 
lheel 55 57 
ltoe 58 60 
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APPENDIX B  
VELOCITY FIGURES FOR ALL THE PATIENTS 
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Patient A Before (upper left), After (upper right) and Follow-up (lower) Treatment 
- Shoes Off 
 
 
 
 
 
Patient A Before (upper left), After (upper right) and Follow-up (lower) Treatment 
- Shoes On 
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   Patient C Before and After Treatment 
 
 
 
 
 
Patient D Before (left) and After (middle) - Shoes Off 
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Patient D Before (left) and After (middle) - Shoes On 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient E Before (left), After (middle) and Follow-up (right) Treatment 
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Paitent B Before (left), After (middle) and Follow-up (right) Treatment - Shoes Off 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient B Before (left), After (middle) and Follow-up (right) Treatment - Shoes On 
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